ATF1 and RAS in exosomes are potential clinical diagnostic markers for cervical cancer. (10th October 2017)

• Record Type: Journal Article
• Authors: Shi, Yanhua; Wang, Wei; Yang, Baozhi; Tian, Hongge
• Is Part Of: Cell biochemistry and function. Volume 35:Number 7(2017)
• Page Start: 477
• Page End: 483
• Publication Date: 2017-10-10
• Subjects: ATF1 -- cervical cancer -- early diagnosis -- exosomes -- RAS; Cytochemistry -- Periodicals; Cell metabolism -- Periodicals; Biochemistry -- Periodicals; Cytology -- Periodicals; 572
• DOI: 10.1002/cbf.3307
• Languages: English
• ISSNs: 0263-6484

Abstract

Abstract : Cervical cancer is one of the most common cancers among women worldwide. It is highly lethal yet can be treated when found in early stage. Thus, early detection is of significant important for early diagnosis of cervical cancer. Exosomes have been used as biomarkers in clinical diagnosis. It is unknown that whether blood exosomes associated with cervical cancer can be detected and if these exosomes can accurately represent the developmental stage of cervical cancer. Mouse models were made out of a relapsed cervical cancer patient's tumour sample for original and recurrent cervical cancer, and gene analysis in both tumours and exosomes in these mouse models were performed. We found that activating transcription factor 1 (ATF1) and RAS genes were significantly up‐regulated in tumours of both primary and recurrent cervical cancer mouse model, and they can also be detected in the blood exosomes of the mouse model. Our results indicated that ATF1 and RAS could be potential candidate biomarkers for cervical cancer in early diagnosis. ATF1 and RAS genes were found significantly elevated in tumours of primary and recurrent cervical cancer mouse model, and they were also detected in the blood exosomes. Therefore, ATF1 and RAS could be used as a diagnostic marker for cervical cancer in the future.